The Novavax vaccine has shown 90% efficacy in phase 3 clinical trials in the UK that enrolled more than 15,000 participants aged 18-84 years, of whom 27% were over 65. The vaccine was shown to work against the more infectious UK strain, according to the company.from Industry-Economic Times
Read The Rest:economictimes...
